2상모집 중

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

연구 개요

Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 62 weeks.

스폰서
리드: 일라이 릴리
적응증
Colitis, Ulcerative, Crohn Disease
중재
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
목표 등록
60
시작일
2026-05-04
완료(예정)
2028-03-01

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.